JP2010505814A - ポリグルタミン伸長関連疾患を治療するための塩素グアナベンズ誘導体の使用 - Google Patents
ポリグルタミン伸長関連疾患を治療するための塩素グアナベンズ誘導体の使用 Download PDFInfo
- Publication number
- JP2010505814A JP2010505814A JP2009530966A JP2009530966A JP2010505814A JP 2010505814 A JP2010505814 A JP 2010505814A JP 2009530966 A JP2009530966 A JP 2009530966A JP 2009530966 A JP2009530966 A JP 2009530966A JP 2010505814 A JP2010505814 A JP 2010505814A
- Authority
- JP
- Japan
- Prior art keywords
- psi114
- disease
- treatment
- polyglutamine
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010040003 polyglutamine Proteins 0.000 title claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
- 201000010099 disease Diseases 0.000 title claims abstract description 19
- 229920000155 polyglutamine Polymers 0.000 title claims abstract description 17
- 229910052801 chlorine Inorganic materials 0.000 title claims abstract description 5
- 239000000460 chlorine Substances 0.000 title abstract description 4
- -1 chlorine guanabenz derivatives Chemical class 0.000 title abstract description 3
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 210000003591 cerebellar nuclei Anatomy 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 210000000463 red nucleus Anatomy 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229960004553 guanabenz Drugs 0.000 description 13
- 238000009825 accumulation Methods 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000003119 immunoblot Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 102000029797 Prion Human genes 0.000 description 6
- 108091000054 Prion Proteins 0.000 description 6
- 102100035071 Vimentin Human genes 0.000 description 6
- 108010065472 Vimentin Proteins 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 210000005048 vimentin Anatomy 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 3
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 3
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003050 guanabenz acetate Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004898 n-terminal fragment Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 102000016252 Huntingtin Human genes 0.000 description 2
- 108050004784 Huntingtin Proteins 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- RATZLMXRALDSJW-UHFFFAOYSA-N 2-(2-ethyl-3H-benzofuran-2-yl)-4,5-dihydro-1H-imidazole Chemical compound C1C2=CC=CC=C2OC1(CC)C1=NCCN1 RATZLMXRALDSJW-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000007372 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 102000004321 Atrophin-1 Human genes 0.000 description 1
- 108090000806 Atrophin-1 Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000036993 Frustration Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- CQXADFVORZEARL-UHFFFAOYSA-N Rilmenidine Chemical compound C1CC1C(C1CC1)NC1=NCCO1 CQXADFVORZEARL-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010065954 Stubbornness Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000389 anti-prion effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950001765 efaroxan Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000764 rilmenidine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- ZIWHWEYDKGWAOG-ZIDSAKIASA-H tricalcium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO ZIWHWEYDKGWAOG-ZIDSAKIASA-H 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
の分子または薬剤的に許容されるその塩の使用に関する。
a.結果
凝集タンパク質の強力な阻害剤を単離するために、酵母ベースの比色ハイスループット法(colorimetric high-throughput method)が開発された(酵母プリオンベース試験、特許出願EP 1551992)。種々のライブラリから約15000分子がスクリーニングされ、その中から、別の疾患の治療のために既に用いられている医薬であるグアナベンズ(この研究においてPsi114と呼ばれる)が、酵母プリオンに対するその強力な活性に起因するさらなる研究のために選択された。クロログアナベンズ(Cl−Psi114)は、医薬品化学によって得られ、酵母の抗プリオンスクリーンにおいてPsi114より活性であることが明らかにされた(図1a)。GuHCL(酵母プリオンの十分に特徴付けられた阻害剤)は、コントロールとして示された。本発明者らは、酵母プリオンの最も活性な阻害剤であるPsi114およびCl−Psi114を一過性にトランスフェクトされたHDの細胞モデルにおいて試験した。293T細胞は、48のグルタミンを有するハンチンチン誘導体のN−末端フラグメントを発現する構築物をトランスフェクトされ、示された用量の化合物により処理された。このモデルは、発現レベルおよび過剰発現polyQ誘導体の凝集性向が非常に高いために、化合物の活性を試験するために非常に厳密なものである。この厳密な系において、コンゴーレッドは、500μMの用量でほぼ検出不能な活性を有する。トランスフェクション後48時間においてSDS抽出が行われ、免疫ブロットおよびフィルタ遅延アッセイの両方によって分析された。細胞タンパク質であるビメンチンの測定は、細胞タンパク質濃度が細胞濃度に従って変動するので、毒性評価として用いられた。ビメンチンのレベルが、それぞれ0〜32μMまたは16μMのPsi114またはCl−Psi114の範囲で処理にわたり大体一定のままである一方で、可溶性のHtt48および凝集Htt48のレベルの両方が、両方の化合物による処理において用量依存性に減少している(図1(b)および(c))。特に、Psi114によって誘発される可溶性Htt48についての減少は、8μMにおいて既に目に見えている(図1b)一方で、凝集物質についてのその効果(図1c)は進行が妨げられており、このことは、Psi114は、Htt48の蓄
積においての早期の事象をターゲットにしていることを示唆している。化合物Psi114およびCl−Psi114は、一過性にトランスフェクトされたHDの細胞モデルにおいてハンチンチンの病原性フラグメントの蓄積を効果的に低減させる。
Psi114およびCl−Psi114は、それらの可溶性および不溶性の形態の両方においてpolyQの蓄積を低減させる。治療的なアプローチを開発する際に、ハンチンチンの病原性フラグメントを特にターゲットにすることは、ハンチンチンは必須の遺伝子であるため、基本的関心事である。本発明者らは、ハンチンチンのN末端フラグメントのために試験されたのと同一の抽出物中の内因性の完全長ハンチンチンについての活性な化合物の効果を試験した。Psi114およびCl−Psi114は、293T細胞中の完全長内因性ハンチンチンのレベルについて効果を有していない一方で、これらの2種の化合物は、ハンチンチンのN末端病原性フラグメントの蓄積を効果的に低減させる(図1b)。Cl−Psi114も、HD患者のリンパ芽球様細胞系において完全長内因性ハンチンチンのレベルについての効果を有していない。まとめると、これらのデータにより、化合物Psi114およびCl−Psi114は、ハンチンチンタンパク質の疾患関連N末端フラグメントの蓄積を特に低減させることが示される。
グアナベンズ(Psi114)およびクロログアナベンズ(Cl−Psi114)の効果は、今までのところ、活発に***している酵母および293T細胞において試験された(Lunkes et al.,1998)。神経細胞はハンチントンのターゲットであり、ミスフォールドしたタンパク質の蓄積の脅威が神経細胞中の***終了細胞を悪化させるため、本発明者らは、次に、HDのNG108-15神経細胞様細胞モデルにおけるPsi114およびCl−Psi114の効果を試験した。NG108-15細胞は、73Qの繰り返し(T73)を有する切頭(truncated)ハンチンチンの発現および分化のために誘導された。
経口投与に適した錠剤の組成:
酢酸グアナベンズ
ラクトース
リン酸カルシウム
コーンスターチ
コロイダルシリカ
ポビドン
ステアリン酸
可溶性スターチ
薬量学
4mgの酢酸グアナベンズ、1日2回。
Bach, S. et al . Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 21, 1075-81. Epub 2003 Aug 10. (2003)
Lunkes, A. & Mandel, J. L. A cellular model that recapitulates major pathogenic steps of Huntington' s disease. Hum MoI Genet 7, 1355-61. (1998)
Lunkes, A. et al . Proteases acting on mutant huntingtin generate cleaved products that differentially built up cytoplasmic and nulear inclusions. MoI Cell 10, 259-69. (2002)
Claims (5)
- ポリグルタミン伸長関連疾患は、ハンチントン病、ケネディ病、筋萎縮性側索硬化症、小脳性自律神経性運動失調、歯状核赤核・淡蒼球ルイ体萎縮症、または球脊髄性筋萎縮症である、請求項1〜4のいずれかによる使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06291547.5 | 2006-10-04 | ||
EP06291547A EP1908464A1 (en) | 2006-10-04 | 2006-10-04 | Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases |
PCT/IB2007/004177 WO2008041133A2 (en) | 2006-10-04 | 2007-10-03 | Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010505814A true JP2010505814A (ja) | 2010-02-25 |
JP5264739B2 JP5264739B2 (ja) | 2013-08-14 |
Family
ID=37492124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009530966A Active JP5264739B2 (ja) | 2006-10-04 | 2007-10-03 | ポリグルタミン伸長関連疾患を治療するための塩素グアナベンズ誘導体の使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7932422B2 (ja) |
EP (2) | EP1908464A1 (ja) |
JP (1) | JP5264739B2 (ja) |
AT (1) | ATE548032T1 (ja) |
CA (1) | CA2664933C (ja) |
WO (1) | WO2008041133A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505815A (ja) * | 2006-10-04 | 2010-02-25 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク セエンエールエス | プリオンベースの疾患を治療するための塩素グアナベンズ誘導体の使用 |
JP2017521494A (ja) * | 2014-07-02 | 2017-08-03 | インフレクティス・バイオサイエンス | プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用 |
JP2018517402A (ja) * | 2015-04-08 | 2018-07-05 | メディカル リサーチ カウンシルMedical Research Council | ホスファターゼ選択的および非選択的なホスファターゼ阻害剤を選択するための方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2893844B1 (fr) * | 2005-11-28 | 2008-02-01 | Centre Nat Rech Scient | Utilisation du guanabenz et de ses derives pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
WO2012048330A2 (en) * | 2010-10-08 | 2012-04-12 | The Mclean Hospital Corporation | Treatment of motor neuron disease |
GB201300435D0 (en) * | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
US10905663B2 (en) | 2013-03-05 | 2021-02-02 | The University Of Chicago | Treatment of demyelinating disorders |
RU2706002C2 (ru) | 2014-07-02 | 2019-11-13 | Инфлектис Байосайенс | Производные о-алкил-бензилиденгуанидина и их терапевтическое использование для лечения заболеваний, связанных с накоплением неправильно свернутых белков |
JP2021529729A (ja) | 2018-05-09 | 2021-11-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | I型ifn依存性病態を処置するためのグアナベンズ又はその誘導体の使用 |
CA3145343A1 (fr) | 2019-07-09 | 2021-01-14 | Universite De Bretagne Occidentale (Ubo) | Nouveaux composes inhibiteurs de la pfar |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050148673A1 (en) * | 2002-07-11 | 2005-07-07 | Harbut Ronald E. | Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2204920T3 (es) * | 1993-05-27 | 2004-05-01 | Cenes Limited | Guanidinas substituidas terapeuticas. |
-
2006
- 2006-10-04 EP EP06291547A patent/EP1908464A1/en not_active Withdrawn
-
2007
- 2007-10-03 US US12/311,433 patent/US7932422B2/en active Active
- 2007-10-03 CA CA2664933A patent/CA2664933C/en active Active
- 2007-10-03 EP EP07859240A patent/EP2066312B1/en active Active
- 2007-10-03 WO PCT/IB2007/004177 patent/WO2008041133A2/en active Application Filing
- 2007-10-03 AT AT07859240T patent/ATE548032T1/de active
- 2007-10-03 JP JP2009530966A patent/JP5264739B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050148673A1 (en) * | 2002-07-11 | 2005-07-07 | Harbut Ronald E. | Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505815A (ja) * | 2006-10-04 | 2010-02-25 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク セエンエールエス | プリオンベースの疾患を治療するための塩素グアナベンズ誘導体の使用 |
JP2017521494A (ja) * | 2014-07-02 | 2017-08-03 | インフレクティス・バイオサイエンス | プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用 |
JP2018517402A (ja) * | 2015-04-08 | 2018-07-05 | メディカル リサーチ カウンシルMedical Research Council | ホスファターゼ選択的および非選択的なホスファターゼ阻害剤を選択するための方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2008041133A3 (en) | 2008-10-16 |
US20100036166A1 (en) | 2010-02-11 |
CA2664933C (en) | 2014-12-09 |
US7932422B2 (en) | 2011-04-26 |
EP2066312B1 (en) | 2012-03-07 |
EP1908464A1 (en) | 2008-04-09 |
EP2066312A2 (en) | 2009-06-10 |
CA2664933A1 (en) | 2008-04-10 |
JP5264739B2 (ja) | 2013-08-14 |
ATE548032T1 (de) | 2012-03-15 |
WO2008041133A2 (en) | 2008-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5264739B2 (ja) | ポリグルタミン伸長関連疾患を治療するための塩素グアナベンズ誘導体の使用 | |
US11517572B2 (en) | Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid | |
US20200368247A1 (en) | Cenicriviroc for the treatment of fibrosis | |
US20200163915A1 (en) | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective rxr agonists | |
Busse et al. | Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients | |
US20220339169A1 (en) | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist | |
US20200338097A1 (en) | Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions | |
US20210299154A1 (en) | Senolytic Compositions And Uses Thereof | |
JP2011518119A (ja) | 4−フェニル酪酸(4pba)およびその医薬上許容し得る塩についての新規用途 | |
JP2022535644A (ja) | 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法 | |
KR20220127832A (ko) | 근위축성 측삭 경화증 및 관련 장애의 치료 | |
CN107205976A (zh) | 用于治疗溶酶体病症的组合物和方法 | |
Chen et al. | Maraviroc, an inhibitor of chemokine receptor type 5, alleviates neuroinflammatory response after cerebral Ischemia/reperfusion injury via regulating MAPK/NF-κB signaling | |
JP2020508343A (ja) | 医薬組成物の調製におけるシトクロムbc1複合体阻害剤の使用 | |
Malahias et al. | Postoperative serum cytokine levels are associated with early stiffness after total knee arthroplasty: a prospective cohort study | |
Zheng et al. | HDAC3 promotes pulmonary fibrosis by activating NOTCH1 and STAT1 signaling and up-regulating inflammasome components AIM2 and ASC | |
CN109415342A (zh) | 用于治疗纤维化的wnt抑制剂 | |
Xue et al. | Nomilin targets the Keap1‐Nrf2 signalling and ameliorates the development of osteoarthritis | |
US11844767B2 (en) | Composition and methods for stimulating clearance of amyloid-beta protein | |
US20240059685A1 (en) | Piezo1 agonists for the promotion of bone formation | |
CN111417647A (zh) | 新型senolytic肽 | |
US10328051B2 (en) | Proline or proline derivatives for the treatment of dementia | |
TW200529847A (en) | Pharmaceutical composition for use in the treatment of chronic fatigue syndrome or fibromyalgia or associated functional symptoms of fibromyalgia | |
US10143666B2 (en) | Small molecule inhibitors targeting CAG-repeat RNA toxicity in polyglutamine diseases | |
US11779588B2 (en) | Method of treating amyotrophic lateral sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130430 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5264739 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313114 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |